FDA Pushes Enrollment of Underrepresented Populations in Clinical Trials with Recent ‘Race and Ethnicity Diversity Plan' Draft Guidance
CMS Issues New No Surprises Act FAQS on Good Faith Estimates and the Overall Requirements and Exceptions for Healthcare Providers
